Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
RNPC3‐JAK2 fusion + Chr t(1;9)(p13;p22)
i
Other names:
RNPC3, RNA Binding Region (RNP1, RRM) Containing 3, SNRNP65, RBM40, U11/U12 Small Nuclear Ribonucleoprotein 65 KDa Protein, RNA-Binding Region-Containing Protein 3, RNA-Binding Motif Protein 40, U11/U12 SnRNP 65 KDa Protein, RNA-Binding Protein 40, U11/U12 SnRNP 65K, U11/U12-65K, KIAA1839, RNP, FLJ20008, IGHD5, JTK10, THCYT3, JAK2, Janus Kinase 2, Tyrosine-Protein Kinase JAK2, JAK-2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3717
;
55599
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
JAK2 V617F (4)
JAK2 mutation (4)
JAK2 F547 (2)
JAK2 F694L (1)
JAK2 R683G (1)
JAK2 R938Q (1)
JAK2 mutation + CRLF2 rearrangement (1)
JAK2 rearrangement (1)
JAK2 I682F (0)
JAK2 QGinsR683 (0)
JAK2 rearrangement (0)
JAK2 R867Q (0)
JAK2 V617F (4)
JAK2 mutation (4)
JAK2 F547 (2)
JAK2 F694L (1)
JAK2 R683G (1)
JAK2 R938Q (1)
JAK2 mutation + CRLF2 rearrangement (1)
JAK2 rearrangement (1)
JAK2 I682F (0)
JAK2 QGinsR683 (0)
JAK2 rearrangement (0)
JAK2 R867Q (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
RNPC3‐JAK2 fusion + Chr t(1;9)(p13;p22)
B Acute Lymphoblastic Leukemia
RNPC3‐JAK2 fusion + Chr t(1;9)(p13;p22)
B Acute Lymphoblastic Leukemia
ruxolitinib
Resistant: C4 – Case Studies
ruxolitinib
Resistant
:
C4
ruxolitinib
Resistant: C4 – Case Studies
ruxolitinib
Resistant
:
C4
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.